ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7804
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,131.52
0.55%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Daxor Corporation (DXR)

  7. Daxor Corporation (DXR) Noticias

DXR Daxor Corporation

9.5527
-0.121 (-1.25%)
10 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Daxor Corporation DXR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.121 -1.25% 9.5527 15:10:38
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.67 9.49 9.67 9.5527 9.6737
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202407:00GLOBENew Studies Prove the Clinical Benefits of Daxor’s Blood..
15/4/202407:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
10/4/202407:00GLOBEDaxor Corporation Announces New Hospital Account at Leading..
01/4/202407:00GLOBEDaxor Corporation to Exhibit at the American College of..
25/3/202407:00GLOBEDaxor Corporation Acquires Volumex® and Megatope® From Its..
22/3/202407:00GLOBEDaxor Corporation to Hold Investor Call Discussing Fiscal..
18/3/202413:18GLOBEDaxor Corporation CEO and President Michael Feldschuh..
11/3/202407:00GLOBEDaxor Announces Sales to Three New Hospitals Furthering..
08/3/202412:49EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
08/3/202407:00GLOBEMulti-Center Study Presented by Duke at Heart Failure..
06/3/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202416:28EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
29/2/202415:15EDGAR2Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of..
26/2/202407:00GLOBEDaxor Corporation to Exhibit at the Technology and Heart..
12/2/202407:00GLOBEDaxor Corporation Starts 2024 with Ongoing Growth in New..
07/2/202407:00GLOBEDaxor Corporation Closes Q4 2023 with Growth in New Sales to..
29/1/202407:00GLOBEDaxor Corporation to Exhibit at the Society of Nuclear..
16/1/202407:00GLOBEDaxor Corporation to Exhibit at the Society for Critical..
09/1/202407:00GLOBEDAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME..
02/1/202407:52EDGAR2Form 8-K - Current report
02/1/202407:30GLOBEDaxor Corporation Submits Dual 510(k)/CLIA-waiver..
06/12/202314:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202319:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202305:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202312:53EDGAR2Form NPORT-P - Monthly Portfolio Investments Report on Form..
24/11/202310:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202307:00GLOBENew Randomized Controlled Trial Demonstrates the Efficacy of..
13/11/202305:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202307:00GLOBEDaxor Corporation Awarded New Patent for Remote Monitoring..
02/11/202317:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/10/202316:27EDGAR2Form 8-K - Current report
16/10/202311:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202307:00GLOBEExpert Panelists Advocate Use of Daxor’s Technology to..
11/10/202307:00GLOBENew Data from Banner University Medicine Demonstrating..
04/10/202307:00GLOBEDaxor Corporation Awarded Support from the National..
27/9/202307:00GLOBEDaxor Corporation to Exhibit at the Heart Failure Society of..
26/9/202308:14EDGAR2Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
26/9/202307:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
20/9/202315:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202311:00GLOBEDaxor Corporation Awarded $305K Grant from the National..
07/9/202308:15GLOBEDaxor Corporation to Present at the H.C. Wainwright 25th..
28/8/202315:15GLOBEDaxor Corporation CEO and President Michael Feldschuh..
28/8/202315:05GLOBEDaxor Corporation Reports a 20.64 Percent Increase in..
28/8/202315:01EDGAR2Form N-CSRS - Certified Shareholder Report, Semi-Annual
15/8/202306:14EDGAR2Form N-PX - Annual Report of proxy voting record of..
10/8/202307:00GLOBEJACC-HF Reports Successful Heart Failure Trial With Daxor..
13/7/202315:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202315:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202315:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
DXR
Daxor
BIT
P13DC6
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados